On December 12, 2022, Novozymes and Chr. Hansen finalized their agreement to merge, establishing Novonesis as a leading global biosolutions partner. With all regulatory approvals secured and the merger officially completed, Novonesis is poised to revolutionize biosolutions, leveraging the collective strengths of both companies. Ester Baiget, Novonesis’ President and CEO, emphasizes the commitment to innovation and transformative solutions, aiming to enhance production, consumption, and overall living. Cees de Jong, Chairman of Novonesis, expresses satisfaction with the creation of a global biosolutions leader, focusing on powerful solutions, sustainable growth, and positive societal and environmental impact. The combined entity boasts a diverse portfolio, generating approximately EUR 3.7 billion in annual revenue, with a strategic emphasis on promoting healthier lives, improving food quality, reducing chemical usage, and fostering climate-neutral practices. With a global presence in research, development, and manufacturing, Novonesis is supported by a dedicated workforce of around 10,000 individuals, dedicated to realizing the potential of biosolutions.

Read The Full Article – https://www.novozymes.com/en/news/combination-novozymes-and-chr-hansen-now-successfully-completed-creating-novonesis-leading